Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials

Jakub K Simon,Stephen B Kennedy,Barbara E Mahon,Sheri A Dubey,Rebecca J Grant-Klein,Ken Liu,Jonathan Hartzel,Beth-Ann G Coller,Carolee Welebob,Mary E Hanson,Rebecca F Grais

Vaccine（2022）

引用 3|浏览9

暂无评分

摘要

•In 3 phase 2/3 trials in Africa, vaccination with ERVEBO™ yielded robust immune responses.•Baseline seropositive participants had higher binding antibody concentrations postvaccination.•There was no association between immune response and age.•The immune response was robust & durable regardless of sex, age, or pre-existing antibody level.

查看译文

关键词

Ebola,Vaccine,Immunogenicity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要